Orexo Achieves Significant Progress with OX390 in Groundbreaking In-Vivo Study#Sweden#Orexo#AmorphOX#Uppsala#OX390
Orexo Achieves Significant Progress with OX390 in Groundbreaking In-Vivo Study
Orexo's latest in-vivo study reveals promising results for OX390, a potential treatment for opioid overdoses linked to certain dangerous substances. This marks a pivotal step in addressing public health challenges.
third-news.com
May 19, 2026 at 3:00 PM
Orexo Announces Breakthrough in OX390 with Positive In-Vivo Study Results for Emergency Treatment#Sweden#Orexo#AmorphOX#Uppsala#OX390
Orexo Announces Breakthrough in OX390 with Positive In-Vivo Study Results for Emergency Treatment
Orexo has reported promising in-vivo study outcomes for OX390, an emergency treatment for xylazine and medetomidine overdoses, demonstrating rapid nasal absorption of atipamezole.
third-news.com
May 19, 2026 at 2:51 PM